Olympus Medical Systems India Pvt. Ltd. (OMSI), an Olympus Group company, today announces the successful inauguration of ...

NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s ...